{"schema_version":"secwatch.filing_event.v1","accession":"0001723128-23-000012","form_type":"8-K","ticker":"AMRX","cik":"0001723128","company_name":"Amneal Pharmaceuticals, Inc.","filed_at":"2023-04-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.235603+00:00","generated_at":"2026-06-17T01:25:39.445404+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Amneal reports preliminary Q1 2023 revenue $550-560M (+12% YoY); affirms FY guidance","bullets":["Net revenue $550-560M, up ~12% YoY; loss before taxes $10M-$0 (improvement ~50%).","Adjusted EBITDA $115-120M, up ~18% YoY.","Long-term debt $2.692B; net debt reduced to $2.541B from $2.647B at Dec 31.","Management cites strong generics, biosimilars uptake, Rytary/Unithroid growth; IPX203 PDUFA June 30.","Full year 2023 financial guidance affirmed."],"urls":{"canonical":"https://secwatch.observer/filing/0001723128-23-000012","json":"https://secwatch.observer/filing/0001723128-23-000012.json","markdown":"https://secwatch.observer/filing/0001723128-23-000012.md","text":"https://secwatch.observer/filing/0001723128-23-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1723128/000172312823000012/0001723128-23-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1723128/000172312823000012/amrx-20230417.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T01:25:39.445404+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5c45642a18642056d8e669a42f45f0409665f14a","claim":"Amneal Pharmaceuticals, Inc. reported first quarter ended March 31, 2023 results: revenue $550 million to $560 million. Guidance reaffirmed.","evidence_excerpt":"2023. Unaudited Preliminary Financial Results for the First Quarter Ended March 31, 2023 Based on preliminary financial information, Amneal expects to report: • Net revenue of $550 million to $560 million, an increase of approximately 12% compared to the first quarter of 2022 • Loss before income taxes of $10 million to $0, an improvement of approximately 50%","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1723128/000172312823000012/0001723128-23-000012-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"$550 million to $560 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}